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Abstract: The rates of gestational cannabis use have increased despite limited evidence for its safety
in fetal life. Recent animal studies demonstrate that prenatal exposure to ∆9-tetrahydrocannabinol
(∆9-THC, the psychoactive component of cannabis) promotes intrauterine growth restriction (IUGR),
culminating in postnatal metabolic deficits. Given IUGR is associated with impaired hepatic function,
we hypothesized that ∆9-THC offspring would exhibit hepatic dyslipidemia. Pregnant Wistar rat
dams received daily injections of vehicular control or 3 mg/kg ∆9-THC i.p. from embryonic day (E)
6.5 through E22. Exposure to ∆9-THC decreased the liver to body weight ratio at birth, followed by
catch-up growth by three weeks of age. At six months, ∆9-THC-exposed male offspring exhibited
increased visceral adiposity and higher hepatic triglycerides. This was instigated by augmented
expression of enzymes involved in triglyceride synthesis (ACCα, SCD, FABP1, and DGAT2) at
three weeks. Furthermore, the expression of hepatic DGAT1/DGAT2 was sustained at six months,
concomitant with mitochondrial dysfunction (i.e., elevated p66shc) and oxidative stress. Interestingly,
decreases in miR-203a-3p and miR-29a/b/c, both implicated in dyslipidemia, were also observed in
these ∆9-THC-exposed offspring. Collectively, these findings indicate that prenatal ∆9-THC exposure
results in long-term dyslipidemia associated with enhanced hepatic lipogenesis. This is attributed by
mitochondrial dysfunction and epigenetic mechanisms.
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1. Introduction
Cannabis is the most commonly used recreational drug among individuals of reproductive age. In 2019, the Canadian Cannabis Survey found that approximately 21% of
female adolescents and young adults self-reported daily or almost daily use of cannabis,
while 40% reported monthly use [1]. The American College of Obstetricians and Gynecologists has further found that 2–5% of individuals use cannabis during pregnancy, and this
was increased to 15–28% among young women who lived in urban settings and whom were
socioeconomically disadvantaged [2]. Along with the recent legalization of recreational
cannabis in Canada and select American states, the use of cannabis during pregnancy
has become increasingly popular despite limited evidence of its safety. Many pregnant
individuals use cannabis to diminish nausea, anxiety and depression, as they believe it to
be a ‘safe’ and natural alternative to prescription medications [3–5]. Alarmingly, gestational
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exposure to cannabis can increase the risk for adverse neonatal outcomes, including low
birth weight and preterm delivery [6–8]. However, these studies are confounded by that
fact that cannabis users are more likely to concurrently abuse other drugs, such as alcohol
and tobacco [9], highlighting the need for animal studies that focus on the effects of specific
constituents of cannabis (i.e., ∆9-tetrahydrocannabinol [∆9-THC] and cannabidiol [CBD])
on short- and long-term maternal-fetal outcomes [9].
Cannabis is composed of several distinct compounds that stimulate the endocannabinoid system via the interaction with cannabinoid receptor type 1 (CB1R) and CB2R. These
receptors are highly expressed throughout the central nervous system (CNS). Therefore,
their activation by cannabinoids has a profound effect on mood, pain, memory and appetite [10]. At the same time, CB1R and CB2R are localized in peripheral metabolic tissues,
suggesting that the endocannabinoid system has additional roles outside of neurocognitive
function [11–14]. Many cannabinoids are also lipophilic and able to cross the placental
barrier, thereby entering fetal circulation and allowing for activation of CB1R and CB2R [15].
While the activation of the endocannabinoid system is essential for the maintenance of
pregnancy, the presence of exogenous cannabinoids can also directly interfere with fetal
growth and development through the disruption of endocannabinoid signaling. Gestational exposure to ∆9-THC, the principal psychoactive component of cannabis, has been
demonstrated to promote placental insufficiency and symmetrical intrauterine growth
restriction (IUGR) in rodents, characterized by low birth weight and reduced neonatal
organ weight [16–21]. Notably, the liver-to-body weight ratio is reduced in ∆9-THC offspring, followed by rapid catch-up growth in the first three weeks of life [21]. While the
developmental origins of health and disease (DOHaD) postulates that there is an inverse
relationship between birth weight and metabolic health, the role of gestational ∆9-THC
exposure on postnatal hepatic function has not yet been investigated.
The liver has a critical role in controlling lipid metabolism, which involves the synthesis and degradation of structural and functional lipid molecules. Naturally, impaired
liver function leads to dyslipidemia, whereby triglycerides and cholesterol become elevated in the liver and plasma. Dyslipidemia is a well-characterized attribute of the
metabolic syndrome that often accompanies obesity. Therefore, individuals with either
of these conditions exhibit an increased risk for developing diabetes and cardiovascular
disease [22]. Moreover, epidemiological studies have identified that low birth weight
individuals with decreased liver-to-body weight ratio are more likely to be obese and
have non-alcoholic fatty liver disease (NAFLD) during childhood and adult life [23–29].
Similar trends have been found in studies of rodent IUGR offspring. We previously shown
that maternal nicotine exposure leads to elevated hepatic and circulating triglycerides
in adult male offspring, while protein-restricted adult males have increased hepatic and
circulating cholesterol [30,31]. Hepatic hyperlipidemia often occurs due to divergent synthesis and metabolism of free fatty acids, which can be of dietary, circulating or de novo
origin [32]. In particular, de novo lipogenesis is a highly regulated, multi-step process
that involves the esterification of fatty acids to triglycerides through the action of numerous enzymes. Initially, acetyl-coA carboxylase (ACCα) catalyzes the carboxylation
of acetyl-coA to malonyl-coA, which acts as a substrate for fatty acid synthase (FAS) in
generating saturated fatty acids [32,33]. Stearoyl-coA desaturase-1 (SCD-1) then converts
these saturated fatty acids into monounsaturated fatty acids (MUFAs), which undergo
various elongation reactions to generate the long chain fatty acids that feed into triglyceride
synthesis pathways [34]. The cytosolic transport of these long chain fatty acids is mediated
by various fatty acid binding proteins (FABPs), which are highly expressed in tissues that
control lipid metabolism. Importantly, the diacylglycerol acyltransferase (DGAT) enzyme
catalyzes the terminal step of triglyceride synthesis [35,36]. Studies of the growth-restricted
liver demonstrate that many of these enzymes are particularly sensitive to developmental
reprogramming, as their abundance and activity levels change with exposure to a variety of
gestational insults leading to long-term dyslipidemia [30,37–39]. That said, the underlying
mechanisms linking a poor in utero environment to these metabolic deficits remain elusive.

Int. J. Mol. Sci. 2021, 22, 7502

3 of 24

Oxidative stress and mitochondrial dysfunction occur with many metabolic pathologies, including hepatic dyslipidemia. Many studies have shown that growth-restricted offspring exhibit oxidative stress and impaired mitochondrial metabolism in the liver [40–45].
Therefore, it is possible that mitochondrial dysfunction precedes dyslipidemia in IUGR
offspring. This may be mediated, in part, by the adaptor protein p66Shc, which is known to
accelerate the mitochondrial production of ROS [46]. Human and animal studies indicate
that the p66Shc-induced oxidative signal is involved in the accumulation of intracellular lipids, leading to obesity and NAFLD [47,48]. Not surprisingly, growth-restricted
offspring display increased levels of p66Shc in the liver, kidney, and pancreas at birth
and in postnatal life [45,49,50]. Furthermore, using a rodent model of maternal protein
restriction, we have also shown that adult male offspring have increased hepatic protein
abundance of p66Shc following postnatal catch-up growth [45]. These same offspring
also have aberrant expression of various microRNAs (miRs) in the liver, so it is possible
that the expression of genes involved in de novo lipogenesis and mitochondrial function
may be regulated via epigenetic mechanisms [51]. Based on the fact that gestational exposure to ∆9-THC leads to compromised liver growth, the present study investigates the
effects of ∆9-THC on hepatic lipid metabolism in the exposed offspring. Given the role of
mitochondria in metabolic disease and the growth-restricted liver, we hypothesized that
∆9-THC-exposed offspring would exhibit oxidative stress and mitochondrial dysfunction,
along with aberrant expression of miRs that are known to result in dysmetabolism.
2. Results
2.1. Gestational Exposure to ∆9-THC Leads to Hepatic Catch-Up Growth by Three Weeks of Age
At birth (i.e., PND 1), ∆9-THC-exposed offspring exhibited decreased liver to body
weight ratio compared to control offspring (Table 1; p < 0.05). It should be noted that
in this same cohort of vehicle and ∆9-THC offspring, we have published that ∆9-THC
exposure during pregnancy did not lead to changes in maternal food intake, maternal
weight gain, litter size or gestational length [21]. By three weeks of age, these offspring
had exhibited hepatic catch-up growth, as there were no significant differences between
liver to-body-weight ratios of ∆9-THC-exposed offspring and control offspring (Table
1). This is consistent with other rodent models of IUGR, including maternal nicotine
exposure and maternal protein restriction, whereby growth-restricted offspring also undergo catch-up growth by three weeks [31,52]. At three weeks of age, there were also
no differences in liver-to-body weight ratios between male and female offspring of either
treatment group (Table 1), indicating that there were no sex-specific effects of gestational
∆9-THC with respect to hepatic catch-up growth. At six months of age, liver to body
weight ratio remained equal between both groups and sexes (Table 1). It should also
be noted that gestational exposure to ∆9-THC did not significantly affect postnatal food
intake (PND50–60) in either males (vehicle, 19.3 ± 1.5 g food/day/offspring; ∆9-THC,
15.12 ± 2.1 g food/day/offspring) or females (vehicle, 17.7 ± 1.6 g food/day/offspring;
∆9-THC, 20.03 ± 1.9 g food/day/offspring.
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Table 1. Gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC) leads to hepatic catch-up growth
by three weeks and increased visceral adiposity in adult life.
Treatment
Group

Sex

Birth

Both sexes

Liver to Body
Weight Ratio

0.0392 # ± 0.0039

Male
∆9-THC

Female
Both sexes

Control
Adipose to Body
Weight Ratio
∆9-THC

0.0319 a ± 0.0024

a

0.0354 a ± 0.0034

0.0445 ± 0.0017

Female

0.0293



± 0.0018

Six Months

a

0.0458 ± 0.0026

Male
Control

Three Weeks

0.0451 # ± 0.0011

0.0333 # ± 0.0020

0.0459 a ± 0.0010

0.0350 a ± 0.0017

0.0437 a ± 0.0009

0.0351 a ± 0.0022

#

0.0445 ± 0.0020

0.0351 # ± 0.0014

Male

0.01685 a ± 0.0015

Female

0.0202 a ± 0.0025

Both sexes

0.01828 # ± 0.0014

Male

0.0207 a ± 0.0020

Female

0.0234 a ± 0.0022

Both sexes

0.0223  ± 0.0015

Liver growth and visceral adipose deposition were assessed for all offspring by calculating liver to body weight
ratio and adipose to body weight ratio. All data are expressed as means ± SEM (n = 7–18/sex/group). The effects
of ∆9-THC on liver to body weight ratio and visceral adipose to body weight ratio were determined via Student’s
two-tailed unpaired t-test. Sex-specific differences in liver to body weight ratio were assessed using a two-way
ANOVA followed by a Holm-Sidak-corrected multiple comparisons test. Groups labelled with different letters or
symbols are significantly different from each other.

2.2. Adult ∆9-THC-Exposed Offspring Exhibit Elevated Visceral Adiposity and Hepatic
Dyslipidemia Following Gestational Exposure to ∆9-THC
As mentioned previously, adult IUGR offspring are vulnerable to the development
of obesity and hepatic pathologies involved in lipid storage and metabolism. Given that
∆9-THC induces symmetrical IUGR [21], we were interested in comparing the levels of
visceral adipose tissue and hepatic lipids between control and ∆9-THC-exposed offspring
during adult life. At six months, offspring exposed to gestational ∆9-THC exhibited
increased visceral adipose to body weight ratio (Table 1; p < 0.05), suggesting dyslipidemia
in these animals.
That said, this was true only when examining both sexes together, as there were differences in visceral adipose to body weight ratio when examining each sex individually. To
explore this further, we measured hepatic and circulating triglyceride and cholesterol levels
of each sex for both groups at six months of age. While both hepatic and circulating triglyceride and cholesterol levels of ∆9-THC-exposed female offspring remained unchanged at
six months (Figure 1A–D), hepatic triglycerides were elevated in ∆9-THC-exposed males
in comparison to control males and all females (Figure 1A; p < 0.05). Interestingly, hepatic
cholesterol was unaltered in six-month old male offspring exposed to gestational ∆9-THC,
as were circulating triglycerides and cholesterol (Figure 1B–D). Since the differences in
lipid content were observed exclusively in livers of male offspring, we further quantified
hepatic triglycerides and cholesterol in male offspring at an earlier timepoint. At three
weeks of age, hepatic triglycerides and cholesterol were not significantly altered between
control and ∆9-THC-exposed male offspring (Figure 1E,F).
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Figure 1. The effects of gestational ∆9-tetrahydrocannabinol (∆9-THC) on triglyceride and cholesterol levels in the liver
and plasma of exposed offspring at three weeks and six months of age. At six months of age, hepatic triglycerides (A) and
cholesterol (B) were assessed in both male and female offspring (mg of lipid/g of tissue), along with circulating levels
of triglycerides (C) and cholesterol (D; mmol/L). Hepatic triglycerides (E) and cholesterol (F) were also quantified in
three-week old male offspring. Data are expressed as the mean ± SEM. The effects of ∆9-THC in three-week old male
offspring were determined via Student’s two-tailed unpaired t-test, while six-month old offspring results were analyzed
using a two-way ANOVA followed by a Holm-Sidak-corrected multiple comparisons test. Groups labelled with different
letters are significantly different from each other (p < 0.05), while groups labelled ‘ns’ were non-significant from each other.

2.3. Elevated Hepatic Triglyceride Levels Coincide with Increased Diglycerol Acyltransferase and
p66Shc Protein Levels in the Livers of Adult Male ∆9-THC-Exposed Offspring
To gain insight on possible mechanisms involved in the elevation of hepatic triglycerides among adult male ∆9-THC-exposed offspring, we performed western immunoblotting for enzymes involved in the triglyceride synthesis pathway. ∆9-THC-exposed males
exhibited increased DGAT1 (Figure 2F; p < 0.05) and DGAT2 (Figure 2G; p < 0.05) in the
liver at six months of age, while there were no significant differences in hepatic ACCα, FAS,
SCD, or FABP1 (Figure 2B–E). Adult female ∆9-THC-exposed offspring also demonstrated
a significant increase in DGAT2 (Figure 2N; p < 0.05) relative to female controls, while
all other enzymes involved in triglyceride synthesis were unchanged (Figure 2I–M). As
p66Shc is linked to the accumulation of intracellular lipids [47], we further quantified the
relative abundance of p66Shc protein in control and ∆9-THC-exposed offspring. Adult
male offspring exposed to gestational ∆9-THC demonstrated increased hepatic p66Shc protein abundance at 6 months compared to control male offspring (Figure 2H; p < 0.05), while
p66Shc was unchanged in adult female offspring (Figure 2O). Again, because changes were
observed in hepatic lipid content exclusively in adult male offspring, we further examined
the expression of these enzymes in males at three weeks of age. At three weeks, ∆9-THCexposed male offspring had increased protein abundance of DGAT2 (Figure 3G; p < 0.001)
and FABP1 (Figure 3E; p < 0.01). However, protein levels of ACCα, FAS, SCD, DGAT1 and
p66Shc were unchanged in male offspring at three weeks of age (Figure 3B–D,F,H).
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Figure 2. Gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC) leads to upregulation of lipogenic enzymes in male
offspring at six months of age. (A) Representative western immunoblots illustrating hepatic expression of acetyl-coA
carboxylase (ACCα), fatty acid synthase (FAS), stearoyl-coA desaturase (SCD), fatty acid binding protein 1 (FABP1),
diacylglycerol acyltransferase (DGAT) 1, DGAT2, and p66Shc in male and female offspring at six months of age. Protein
abundances of each enzyme for male offspring (B–H) and female offspring (I–O) were normalized to β-Actin ± SEM
(n = 7–8/group). All protein abundances were analyzed using a two-tailed unpaired Student’s t-test. * Significant difference
(p < 0.05).
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Figure 3. Three-week old male offspring exhibit increased lipogenic enzyme expression in the liver following gestational
exposure to ∆9-tetrahydrocannabinol (∆9-THC). (A) Representative western immunoblots illustrating hepatic expression
of acetyl-coA carboxylase (ACCα), fatty acid synthase (FAS), stearoyl-coA desaturase (SCD), fatty acid binding protein 1
(FABP1), diacylglycerol acyltransferase (DGAT) 1, DGAT2, and p66Shc in male offspring at three weeks of age. Protein
abundances of (B) ACCα, (C) FAS, (D) SCD, (E) FABP1, (F) DGAT1, (G) DGAT2 and (H) p66Shc were normalized to β-Actin
± SEM (n = 7–8/group). All protein abundances were analyzed using a two-tailed unpaired Student’s t-test. * Significant
difference (p < 0.05), ** significant difference (p < 0.01), *** significant difference (p < 0.001).

2.4. Gestational Exposure to ∆9-THC Does Not Affect Protein Levels of Enzymes Involved in
Aerobic Metabolism at Six Months of Age
Given that male offspring exhibit altered lipid metabolism and increased p66Shc,
which are both implicated in mitochondrial dysfunction [53,54], we then assessed protein levels of enzymes involved in aerobic metabolism. At six months, the abundance
of mitochondrial transcription factor A (TFAM), a protein that is essential in activating
mitochondrial genome transcription, was unaltered in both male and female offspring
exposed to gestational ∆9-THC (Figure 4B,F). Furthermore, male offspring exhibited no
changes in the ratio of phosphorylated pyruvate dehydrogenase at serine residue 232
(p-PDH[Ser232]) to the total PDH, lactate dehydrogenase subunit A (LDHa), or citrate
synthase (Figure 4C–E). Interestingly, six-month female offspring exposed to gestational
∆9-THC displayed a decrease in the ratio of p-PDH[Ser232] to total PDH (Figure 4G), while
protein levels of LDHa and citrate synthase were unchanged (Figure 4H,I). However, at
three weeks of age, male ∆9-THC offspring exhibited increased levels of TFAM (Figure 5B;
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p < 0.01) and LDHa (Figure 5D; p < 0.01), while the ratio of p-PDH[Ser232] to total PDH
and levels of citrate synthase were unchanged (Figure 5C,E).

Figure 4. Gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC) does not impair aerobic metabolism in male or female
offspring at six months of age. (A) Representative western immunoblots illustrating hepatic expression of mitochondrial
transcription factor A (TFAM), phosphorylated pyruvate dehydrogenase (PDH) to total PDH, lactate dehydrogenase subunit
A (LDHa), and citrate synthase in male and female offspring at six months of age. Protein abundances of each enzyme
for male offspring (B–E) and female offspring (F–I) were normalized to β-Actin ± SEM (n = 7–8/group). All protein
abundances were analyzed using a two-tailed unpaired Student’s t-test. * Significant difference (p < 0.05).
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Figure 5. Three-week old male offspring exposed to ∆9-tetrahydrocannabinol (∆9-THC) in utero
have increased mitochondrial transcription factor A (TFAM) and lactate dehydrogenase subunit A
(LDHa). (A) Representative western immunoblots illustrating hepatic expression of mitochondrial
transcription factor A (TFAM), phosphorylated pyruvate dehydrogenase (PDH) to total PDH, lactate
dehydrogenase subunit A (LDHa), and citrate synthase in male and female offspring at six months of
age. Protein abundances of (B) TFAM, (C) p-PDH[Ser232]/PDH, (D) LDHa and (E) citrate synthase
were normalized to β-Actin ± SEM (n = 7–8/group). All protein abundances were analyzed using a
two-tailed unpaired Student’s t-test. ** Significant difference (p < 0.01).

2.5. Gestational Exposure to ∆9-THC Leads to Altered Hepatic Protein Levels of Superoxide
Dismutase 1 in Adult Male Offspring
Given that the increased p66Shc is also associated with oxidative stress [46], we
further analyzed the abundance of antioxidant enzymes that are critical in combatting the
damaging effects of ROS. Male offspring demonstrated decreased protein levels of SOD1
at six months of age (Figure 6C; p < 0.05), while catalase and SOD2 remained unchanged
at this time point (Figure 6B,D). Lipid peroxidation was also unaffected at six months of
age in male offspring exposed to ∆9-THC, as indicated by levels of 4-hydroxynonenol
(4HNE; Figure 6E). At three weeks, male ∆9-THC-exposed offspring did not exhibit any
changes in catalase, superoxide dismutase (SOD) 1 or SOD2 protein levels (Figure 6F–H).
However, hepatic lipid peroxidation was increased as indicated by elevated levels of 4HNE
(Figure 6I; p < 0.05).
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Figure 6. Gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC) results in hepatic oxidative stress within male
offspring at three weeks and six months of age. (A) Representative western immunoblots illustrating hepatic expression
of catalase, superoxide dismutase (SOD) 1, SOD2 and 4-hydroxynonenol (4HNE) in male offspring at three weeks and
six months. Protein abundance of catalase (B,F), SOD1 (C,G), and SOD2 (D,H) were normalized to β-Actin ± SEM
(n = 7–8/group), while 4HNE abundance (E,I) was expressed as means normalized to total protein abundance ± SEM
(n = 7–8/group). All protein abundances were analyzed using a two-tailed unpaired Student’s t-test. * Significant difference
(p < 0.05).

2.6. Mitochondrial Electron Transport Chain Complexes Are Increased in Male Offspring at Six
Months and Three Weeks of Age Following Gestational Exposure to ∆9-THC
The mitochondrial electron transport chain is known to have significant contribution
to the production of ROS, particularly through the activity of complexes I and III [55].
Given we observed changes in antioxidant and mitochondrial proteins in ∆9-THC
offspring, we next quantified protein levels of each subunit of the electron transport
chain. At six months, male offspring exposed to gestational ∆9-THC exhibited increased
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abundance of complexes I, III, and V (Figure 7B,D,F; p < 0.05), while levels of complexes
II and IV were unchanged (Figure 7C,E). While adult female offspring demonstrated an
increase in the protein abundance of complex I (Figure 7G; p < 0.01), the expression of all
other subunits remained unchanged (Figure 7H–K). At three weeks, male ∆9-THC-exposed
offspring also demonstrated increased levels of complexes I and III (Figure 8B,D; p < 0.05),
while all other complexes were unchanged (Figure 8C,E,F).

Figure 7. Gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC) leads to increased complexes I, III and V of the
electron transport chain in male offspring at six months of age. (A) Representative western immunoblots illustrating hepatic
expression of complexes I–V of the electron transport chain in male and female offspring at six months of age. Protein
abundances of each enzyme for male offspring (B–F) and female offspring (G–K) were normalized to β-Actin ± SEM
(n = 7–8/group). All protein abundances were analyzed using a two-tailed unpaired Student’s t-test. * Significant difference
(p < 0.05), ** significant difference (p < 0.01).
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Figure 8. Gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC) leads to increased complexes I
and III of the electron transport chain in male offspring at three weeks of age. (A) Representative
western immunoblots illustrating hepatic expression of complexes I–V of the electron transport chain
in male offspring at three weeks of age. Protein abundances of complex I (B), II (C), III (D), IV (E) and
V (F) were normalized to β-Actin ± SEM (n = 7–8/group). All protein abundances were analyzed
using a two-tailed unpaired Student’s t-test. * Significant difference (p < 0.05).

2.7. Adult Male Offspring Exposed to Gestational ∆9-THC Exhibit Decreased Hepatic Transcript
Levels of miR-203a-3p and miR-29a/b/c
Various miRs are known to be dysregulated with metabolic disease, and we have
previously shown that IUGR offspring with postnatal catch-up growth exhibit altered
expression of miRs, specifically, miR-29a/b/c [51]. To better understand the potential
mechanisms behind the increase in p66Shc protein levels among adult male ∆9-THCexposed livers, we first investigated whether hepatic transcript abundance of miR-203a-3p,
which silences p66shc [56], was altered in these same offspring. As expected, transcript
abundance of miR-203a-3p was significantly decreased in the livers of adult male offspring
with gestational exposure to ∆9-THC (Figure 9A; p < 0.001). Furthermore, livers from threeweek old male ∆9-THC-exposed offspring displayed a trending increase in miR-203a-3p
transcript abundance, but this change was not significant (Figure 9E). Similar to miR-203a3p, hepatic transcript abundances of miR-29a/b/c was also decreased in six-month old
male offspring exposed to gestational ∆9-THC (Figure 9B–D), while the expression of each
isoform was unchanged at three weeks of age (Figure 9F–H).
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Figure 9. Quantitative RT-PCR analysis of miR-203a-2p and miR-29a/b/c in the livers of male offspring at six months (A–D)
and three weeks (E–H) following gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC). Relative amounts of all miRs
were normalized to that of miRNA standard control. Data are expressed as means ± SEM (n = 7–8/group). Groups at
each time point were compared using Student’s two-tailed unpaired t-test. * Significant difference (p < 0.05), ** significant
difference (p < 0.01), *** significant difference (p < 0.001).

3. Discussion
Impairments in the hepatic lipogenic pathway promote excessive production and storage of intracellular triglycerides, leading to the development of obesity and the metabolic
syndrome [22]. In the current study, we demonstrate that gestational exposure to ∆9-THC
leads to increased adipose to bodyweight ratio at six months of age, along with elevated
hepatic triglyceride levels in adult male offspring. The observed dyslipidemia coincides
with increased hepatic expression of lipogenic enzymes at three weeks and six months of
age, culminating in accelerated de novo lipogenesis during adult life. Our results suggest
that these changes in lipid metabolism occur in a sex-specific manner, as hepatic triglyceride
levels were unchanged in adult female offspring exposed to gestational ∆9-THC. Livers
taken from three-week old ∆9-THC-exposed male offspring also showed increased 4HNE
abundance, suggesting that hepatic lipid peroxidation and oxidative stress first occurs in
early life. Furthermore, oxidative stress and mitochondrial dysfunction appear to persist
into adulthood when hepatic triglycerides are increased. Last, our study provides insight
into the epigenetic mechanisms that may underly hepatic dyslipidemia in growth-restricted
offspring, as adult male offspring exposed to gestational ∆9-THC exhibited decreased expression of miR-203a-3p and miR-29a/b/c, all involved in mitochondrial homeostasis in
the liver.
As mentioned previously, there is an inverse relationship between birth weight and
long-term metabolic health. We have reported that gestational exposure to ∆9-THC leads
to symmetrical IUGR in rodent offspring, followed by whole body and hepatic catch-up
growth by three weeks of age [21]. The occurrence of catch-up growth, or rapid postnatal
weight gain, is believed to further exacerbate the risk for metabolic diseases, such as
obesity, as seen in birth cohorts studying growth-restricted infants from South Africa,
Brazil, and the Unites States [57–59]. Here we show that ∆9-THC-exposed offspring
display increased visceral adipose to body weight ratio at six months of age, indicating the
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development of obesity in adult life. This is consistent with our previous studies of rodent
offspring born from models of maternal nicotine exposure and maternal protein restriction,
whereby visceral obesity was observed in adult offspring following postnatal catch-up
growth [60,61]. Clinically, obese individuals exhibit hypertriglyceridemia in the liver
and plasma, often culminating in hepatic steatosis and later NAFLD [62]. In our model,
gestational exposure to ∆9-THC led to an increase in hepatic triglycerides exclusively in
male offspring at six months of age. Interestingly, there were no differences in the levels of
circulating triglycerides among male offspring, while circulating and hepatic cholesterol
levels of both sexes were also unaffected. We have previously reported that female ∆9-THC
exposed offspring exposed to gestational ∆9-THC do not exhibit differences in circulating
estrogen or testosterone relative to control female offspring, so this protective effect cannot
be attributed to changes in the circulating levels of androgenic hormones [63]. However,
the differences in steroid receptor (i.e., androgen receptor/estrogen receptor) signaling in
the liver might be involved [64,65]. Overall, there is great evidence to suggest that men are
more susceptible than women to the development of hepatic steatosis and NAFLD [66–70].
Studies of healthy men and women demonstrate that men exhibit higher rates of de novo
lipogenesis and decreased dietary fatty acid oxidation; therefore, the sexual dimorphism
observed among ∆9-THC-exposed offspring may be attributed to changes in lipogenesis
and lipolysis [71,72].
Given the sex-specific differences in hepatic triglyceride content of ∆9-THC-exposed
offspring, we next investigated the relative protein abundance of lipogenic enzymes among
male and female adult offspring. At six months of age, male offspring exposed to gestational ∆9-THC exclusively displayed increased levels of both DGAT1 and DGAT2, along
with an increase in the mitochondrial adaptor protein p66Shc. Deletion of DGAT and
p66Shc are both independently associated with reduced intracellular accumulation of
triglycerides [47,73]. Therefore, the upregulation of both DGAT1/2 and p66Shc in the
current study likely mediates the increase in hepatic triglycerides of male ∆9-THC exposed offspring. While adult female ∆9-THC exposed offspring demonstrated increases
in DGAT2, this may not be sufficient in promoting increased de novo lipogenesis in the
liver. Instead, a synergistic interaction of multiple enzymes is necessary to elicit changes
in lipid metabolism. Since we observed lipogenic changes in male offspring exposed to
gestational ∆9-THC in adulthood, we further assessed whether this occurred earlier (e.g.,
three weeks) coinciding with the completion of hepatic catch-up growth. ∆9-THC exposed
male offspring exhibited increased abundance of ACCα, SCD, FABP1 and DGAT2 at three
weeks of age, suggesting that catch-up growth may instigate de novo lipogenesis. Incidentally, recent studies have determined that FABP1 is an important regulator of ∆9-THC
hepatic transport and biotransformation [74,75]. Many hepatic pathophysiologies, including NAFLD, are associated with increased expression of FABP1, while its knockdown
reduces hepatic triglyceride accumulation and lipid peroxidation [76]. This is consistent
with our current study, as three-week old male offspring displayed increased abundance
of 4HNE (i.e., a marker of lipid peroxidation) concomitant with elevated FABP1. Since
FABP1 is involved in ∆9-THC metabolism, it is possible that these offspring have altered
expression of FABP1 in response to exposure to ∆9-THC in utero. Mice with knockdown of
hepatic FABP1 also exhibit decreased expression of DGAT1 and DGAT2 in the liver [76];
therefore, early elevation of FABP1 in ∆9-THC-exposed male offspring could be involved
in the upregulation of DGAT and de novo lipogenesis later in life.
Oxidative stress and mitochondrial dysfunction are highly prevalent among metabolic
diseases involving the liver. Elevated reactive oxygen species (ROS) and mitochondrial
abnormalities are implicated in the pathogenesis of NAFLD. However, the mechanisms by
which this occurs are not completely understood [77–80]. In vitro studies have established
that ROS are detrimental to hepatic lipid metabolism and mitochondrial function, as
treatment of HepG2 cells and primary hepatocytes with hydrogen peroxide promotes the
accumulation of triglycerides and cholesterol [81]. Additionally, lipid-induced elevation of
ROS has been shown to impair mitochondrial function in the human hepatoblastoma C3A
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cell line, along with increased gluconeogenesis and ketogenesis [82]. Numerous animal
models have also found that IUGR offspring exhibit indices of hepatic oxidative stress
(e.g., increased lipid peroxidation and ROS; altered expression and activity of antioxidant
enzymes) and impaired mitochondrial function (e.g., aberrant expression and activity of
pyruvate dehydrogenase, citrate synthase, and complexes of the electron transport chain;
disrupted ATP synthesis) during neonatal and adult life [40–43,45]. In particular, we have
shown that hepatic p66Shc is elevated in adult male offspring subject to maternal protein
restriction attributed to postnatal catch-up growth [45]. P66Shc is a key regulator of cellular
redox state, lifespan, and mitochondrial metabolism, as it interacts with cytochrome C
under conditions of cell stress to stimulate the production of ROS [46]. This mitochondrialinduced oxidative stress often leads to apoptosis, cellular senescence and compromised
aerobic metabolism [46,83–85], making p66Shc an attractive target in mitigating metabolic
disease. Again, studies have also postulated that p66Shc is involved in the accumulation of
intracellular lipids [47]. Here, we found that adult male offspring exposed to gestational ∆9THC have increased protein abundance of p66Shc in the liver, concomitant with decreased
abundance of SOD1. While we did not directly measure hepatic ROS, these results suggest
that oxidative stress occurs in the liver following exposure to gestational ∆9-THC and
catch-up growth. To investigate this further, we assessed the levels of proteins involved
in mitochondrial function and aerobic metabolism (i.e., TFAM, p-PDH[Ser232], LDHa,
citrate synthase, and complexes of the electron transport chain). While the expression of
TFAM, p-PDH[Ser232], LDHa and citrate synthase was unchanged in adult male offspring,
they did have increased amounts of complexes I, III and V. This is noteworthy as increases
in complexes I and III are associated with elevated superoxide production via increased
flow of electrons through the subunits of these enzymes [55]. These data, in combination
with our p66Shc and SOD1 findings, further support the idea that these offspring exhibit
hepatic oxidative stress and altered oxidative phosphorylation. Complexes I and III also
increased in three-week old male offspring, suggesting that oxidative stress occurs in early
life following ∆9-THC exposure and catch-up growth.
To date, little is known about the epigenetic mechanisms underlying metabolic diseases in IUGR offspring. One such mechanism is miRs, which are small, non-coding RNA
molecules that silence target genes through mRNA degradation or repressed protein translation. Numerous miRs have been demonstrated to have aberrant postnatal expression in
growth-restricted offspring, leading to cellular stress that precedes impaired function of
metabolic organs [51,86–88]. Recent studies found that the translation of p66Shc protein is
directly inhibited by miR-203a-3p, leading to the attenuation of liver injury and fibrosis
in mice [56]. Here, we observed robust decreases in the expression of miR-203a-3p in
the livers of male offspring exposed to gestational ∆9-THC, but only at six months of
age. This is consistent with the observed increase in p66Shc protein levels at this time
point, indicating that miR-203a-3p may be implicated in the development of oxidative
stress and de novo lipogenesis in these offspring. We further quantified the expression
of miR-29, as we have found this miR family to be altered in the livers of adult male
protein-restricted offspring following catch-up growth [51]. Similar to our findings of miR203a-3p, adult male ∆9-THC-exposed offspring exhibited decreased hepatic expression
of all three isoforms of miR-29 at six months of age. This is of great interest as miR-29
expression is downregulated in patients with advanced liver fibrosis and cirrhosis [89].
Conversely, when present at high levels, miR-29 can alleviate hepatocellular steatohepatitis,
fibrosis and cirrhosis in mice [89–91]. Collectively, given that each of these miRs were
down-regulated exclusively during adult life, it is conceivable that early catch-up growth
of the liver culminates in long-term oxidative stress and impaired hepatic lipid metabolism
through epigenetic regulation of gene expression. Future in vitro studies are warranted
to investigate this relationship further to reveal additional metabolic targets that become
dysregulated with altered expression of miR-203a-3p and miR-29a/b/c in the liver.
In summary, this study demonstrates for the first time that gestational exposure to
∆9-THC leads to hepatic dyslipidemia in adult male offspring. We postulate that this
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occurs as a result of accelerated triglyceride synthesis (i.e., de novo lipogenesis) in the liver,
as multiple lipogenic enzymes are elevated at both three weeks and six months of age.
Given that FABP1 is involved in the metabolism and transport of ∆9-THC, it is possible
that gestational exposure to ∆9-THC in combination with catch-up growth leads to early
elevation of FABP1 in the livers of male offspring. This may further contribute to the
observed increase in lipid peroxidation and lipogenic enzyme expression in male offspring
at three weeks of age. Hepatic lipid overload is known to further increase oxidative stress
and mitochondrial dysfunction. Therefore, this process may occur in a cyclical manner as
indicated in Figure 10. Altered expression of miRs may also contribute to these molecular
changes, as we have indicated that miR-203a-3p and miR-29a/b/c are downregulated in
response to ∆9-THC exposure and catch-up growth. Additional long-term studies will be
important in determining if this later culminates in hepatic pathologies such as NAFLD
and cirrhosis of the liver. Given that ∆9-THC interacts with both the CB1 and CB2 receptors
of the endocannabinoid system, it is also possible that differences in the expression of these
receptors may exist upstream of the observed physiological and molecular effects. That said,
the current study is somewhat limited in that we did not examine the expression of either
CB1R or CB2R. While much remains unknown about the role of prenatal cannabinoids on
offspring outcomes, it is clear that long-term metabolic health becomes compromised as
a result. We have previously shown that exposure to ∆9-THC specifically has effect on
glucose tolerance and cardiovascular function [63,92], and our current study demonstrates
that it further contributes to dyslipidemia. Overall, these data provide great insight into
the effects of gestational ∆9-THC exposure on the development and function of the liver,
as well as the fundamental molecular mechanisms that underlie the metabolic dysfunction
of growth-restricted offspring.

Figure 10. Proposed schematic illustrating the effects of gestational exposure to ∆9-tetrahydrocannabinol (∆9-THC) on
the male rat liver. In summary, in utero exposure to ∆9-THC led to symmetrical intrauterine growth restriction in the
affected offspring, followed by hepatic catch-up growth and increased visceral adiposity during adult life. Male offspring
exposed to gestational ∆9-THC exhibited increased FABP1 and oxidative stress at three weeks of age, leading to increased
de novo lipogenesis at six months. Adult male offspring also demonstrated oxidative stress and mitochondrial dysfunction,
which may occur as a result of elevated hepatic triglyceride content. The presence of oxidative stress and mitochondrial
dysfunction in combination with downregulated miR-203a-3p and miR-29a/b/c may further promote impaired lipid
metabolism of the liver in a positive-feedback manner.
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4. Materials and Methods
4.1. Animals and Experimental Handling
All procedures were performed according to guidelines set by the Canadian Council
of Animal Care, and the animal use protocol was approved by the Animal Care Committee
at The University of Western Ontario (AUP #2019-126, January 2019). All investigators understood and followed the ethical principles outlined by Grundy [93], and the study design
was informed by ARRIVE guidelines [94]. Pregnant female Wistar rats were purchased
from Charles River (La Salle, St. Constant, QC, Canada). Dams arrived at the animal care
facility at gestational day 3 (GD3) and were left to acclimatize to environmental conditions
for three days. All animals were maintained at 22 ◦ C on a 12:12 h light-dark cycle in the animal care facility, while food and water were provided ad libitum for the entire duration of
the experimental protocol. Dams were randomly assigned to receive daily intraperitoneal
(i.p.) injection of either vehicular control (1:18 cremophor:saline) or 3 mg/kg ∆9-THC
(Sigma-Aldrich, St. Louis, MO, USA) from E6.5 to E22 (n = 14, where litter is the statistical
unit) as previously performed [21]. This dose of ∆9-THC was selected as it results in
rodent plasma concentrations (8.6–12.4 ng/mL) that are reflective of those found in human
recreational cannabis smokers (using 6% ∆9-THC) 0–22 h post-inhalation (13–63 ng/mL),
as well as in the aborted fetal tissues of pregnant cannabis users (4–287 ng/mL) [95–97].
This dose and method of delivery has also been demonstrated to have no impact on maternal or litter outcomes in rats [21,98,99]. An oral route of administration was not chosen
as to avoid the poor bioavailability and slowed adsorption of ∆9-THC when ingested
with food, and as edibles are the least popular route of administration of cannabis among
pregnant women [4,100]. Injections were initiated at E6.5 because ∆9-THC can interfere
with implantation of the blastocyst and induce spontaneous abortion [100].
Maternal food intake and body weight were monitored daily throughout the entire
gestational period. Dams were allowed to deliver normally, and all pups were weighed at
birth. Litters were randomly culled to eight offspring per litter to ensure uniformity of litter
size between treatment groups. As previously reported, we and others have found the
selected dose of ∆9-THC has no impact on maternal or litter outcomes [20,21,98,99]. Liver
weights of culled offspring were recorded and compared to body weight as a measure
of fetal growth restriction and postnatal catch-up growth [21]. The food intake of these
offspring was monitored by measuring their daily food consumption from PND50-60,
as previously published [51]. The remaining offspring were fasted for 24 h before being
euthanized via i.p. injection of 100 mg/kg pentobarbital at either postnatal day (PND) 21
or six months of age (n = 8 males/8 females per group), followed by necropsy to examine
the effects of ∆9-THC on metabolic and molecular outcomes. The right medial hepatic
lobe was collected and immediately flash-frozen in liquid nitrogen, followed by storage
at −80 ◦ C until further use. Visceral fat was also weighed and compared to body weight
at six months as a measure of obesity. Blood was also collected, centrifuged, and stored
at −80 ◦ C.
4.2. Hepatic Triglyceride Measurements
Circulating and hepatic triglyceride and cholesterol measurements were detected
using the Cobas® Mira S analyzer as previously published [30]. For triglyceride measurements, triglycerides were hydrolyzed by lipoprotein lipase to glycerol and fatty acids.
Glycerol was then phosphorylated to glycerol-3-phosphate by ATP in a reaction catalyzed
by glycerol kinase (GK). The oxidation of glycerol-3-phosphate was catalyzed by glycerol
phosphate oxidase (GPO) to form dihydroxyacetone phosphate and hydrogen peroxide
(H2 O2 ). In the presence of peroxidase, H2 O2 alters the oxidative coupling of 4-chlorophenol
and 4-aminophenazone to form a red-colored quinoneimine dye, which was measured at
512 nm. The increase in absorbance is directly proportional to the concentration of triglycerides in the sample. For cholesterol measurements, cholesterol esterase cleaved cholesterol
esters, which then were converted to choleste-4-en-3-one and H2 O2 by cholesterol oxidase.
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Cholesterol levels were quantified using a colorimetric assay that measured the breakdown
of H2 O2 via the Trinder reaction as previously described [31].
4.3. RNA Isolation and Quantitative Real-Time PCR Analysis
MicroRNAs were isolated from frozen liver samples using a miRNeasy kit (QIAGEN
Inc., Toronto, ON, Canada), followed by spectrophotometric analysis with a Nanodrop
2000. 0.5 µg of each miRNA sample was then reverse transcribed into cDNA using a
miScript II RT kit (QIAGEN Canada) and stored at −20 ◦ C. Forward sequence primers for
miR-203a-3p, miR-29a, miR-29b, and miR-29c were purchased (QIAGEN Canada), while a
universal reverse sequence primer for miRNAs was used as part of a miScript SYBR green
PCR kit (QIAGEN Canada). MiRNA transcripts were amplified via quantitative real-time
PCR (qRT-PCR) using the Bio-Rad CFX384 Real Time System, using cycling conditions as
previously published [51]. Cq values obtained for miRs of interest were normalized to that
of a miRNA standard control (Ctrl_miRTC_1; QIAGEN Canada), and relative transcript
abundance was calculated for each target using the comparative ∆Ct method.
4.4. Protein Extraction and Western Immunoblot
Whole-cell protein lysates were isolated using the protocol, previously described by
Barra et al. [52] Prior to western immunoblotting, loading samples were prepared using
sample lysates, NuPAGE reducing agent (10×; Invitrogen, Waltham, MA, USA), NuPAGE
LDS sample buffer (4X; Invitrogen), and deionized water. Loading samples were heated
at 70 ◦ C to denature proteins, while a separate set of loading mixes were kept unheated
for mitochondrial OXPHOS immunoblots. Samples were loaded into wells of 4–12%
Bis-Tris gels (Invitrogen) at 20–30 µg per well (n = 8/group), followed by separation via
gel electrophoresis. Proteins were transferred onto PVDF membranes (Thermo Scientific,
Waltham, MA, USA) at 75 V for two hours, followed by one hour of blocking in 1X
Tris-buffered saline/Tween-20 (TBST) buffer with either 5% non-fat milk (Carnation) or
3% bovine serum albumin (BSA; Fisher Scientific, Ottawa, ON, Canada). Membranes
were probed with primary antibodies overnight, followed by probing with secondary
antibodies for one hour (Table 2). To avoid the excessive use of PVDF membranes, multiple
targets of interest were detected on each membrane by cutting the membrane according
to molecular weight and probing with the appropriate primary antibodies in separate
tubes. In the case that a membrane was reused, the primary antibody was removed with
stripping buffer (ThermoFisher Scientific, Waltham, MA, USA), followed by incubation
with secondary antibody and re-imaging to ensure that the initial antibody was removed.
Immunoreactive bands were visualized using BioRad Clarity Max Western ECL Substrate
solution (Bio-Rad Laboratories Canada Ltd., Mississauga, ON, Canada) and imaged using
a BioRad ChemiDoc XRS+ Imaging System. Resulting bands were analyzed using BioRad
Image LabTM Software. Band intensities of target proteins were normalized to β-Actin, as
previously published [45], with the exception of 4-hydroxynonenol which was normalized
to total protein content detected with Ponceau staining [45,101]. Signals for proteins
that were detected on the same membrane were normalized to that of β-Actin from the
same membrane.
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Table 2. Western blot primary and secondary antibodies, dilutions and company/catalogue information.
Antibody Name

Source

Dilution

Company (Catalogue No.)

ACCα (H-76)

Rabbit polyclonal

1:500

Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA (sc-30212)

FAS (C20G5)

Rabbit monoclonal

1:1000

Cell Signaling Technology Inc.,
Danvers, MA, USA (#3180)

SCD (H300)

Rabbit polyclonal

1:250

Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA (sc-30081)

FABP1 (D2A3X)

Rabbit monoclonal

1:1000

Cell Signaling Technology Inc.,
Danvers, MA, USA (#13368)

DGAT1

Rabbit polyclonal

1:1000

Novus Biologicals, Centennial,
CO, USA (NB110-41487)

DGAT2 (4C1)

Mouse monoclonal

1:1000

Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA
(sc-293211)

SHC

Mouse monoclonal

1:1000

BD BioSciences, San Jose, CA,
USA (610879)

TFAM (D5C8)

Rabbit monoclonal

1:1000

Cell Signaling Technology Inc.,
Danvers, MA, USA (8076)

pSer(232) pyruvate
dehydrogenase

Rabbit polyclonal

1:1000

EMD Millipore, Etobicoke, ON,
Canada (AP1063)

Pyruvate dehydrogenase

Rabbit polyclonal

1:1000

Cell Signaling Technology Inc.,
Danvers, MA, USA (2784)

LDHa

Rabbit polyclonal

1:1000

Cell Signaling Technology Inc.,
Danvers, MA, USA (2012)

Citrate Synthase

Rabbit polyclonal

1:1000

Provided by Dr. S. Raha,
McMaster University

Catalase (H-300)

Rabbit polyclonal

1:1000

Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA (sc-50508)

Superoxide dismutase (SOD)-1
(FL-154)

Rabbit polyclonal

1:1000

Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA (sc-11407)

Superoxide dismutase (SOD)-2
(FL-222)

Rabbit polyclonal

1:1000

Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA (sc-30080)

4-hydroxynonenal

Mouse monoclonal

1:1000

R&D Systems, Oakville, ON,
Canada (MAB3249)

OXPHOS rodent cocktail

Mouse monoclonal

1:1000

Abcam Inc., Toronto, ON,
Canada (ab110413)

β-Actin Peroxidase

Mouse monoclonal

1:25,000

Sigma Aldrich Co., St. Louis,
MO, USA (A3854-200UL)

Goat anti-rabbit IgG
HRP-linked (H+L chain)

N/A

1:10,000

Cell Signaling Technology Inc.,
Danvers, MA, USA (7074P2)

Horse anti-mouse IgG
HRP-linked (H+L chain)

N/A

1:10,000

Cell Signaling Technology Inc.,
Danvers, MA, USA (7076S)

4.5. Statistical Analyses
At each timepoint, the selected offspring were taken from separate litters to avoid
litter bias (i.e., n = 1 represents pups from a single dam), where a sample size of n = 7–8 was
used for each sex per group. This sample size was chosen based on our previous studies to
achieve a statistically significant difference with an expected standard deviation of 15%
or less [63,102]. All statistical analyses were performed using GraphPad Prism 9 software.
The results were expressed as means of normalized values ± SEM, and the threshold
for significance was set as p < 0.05. Organ and body weight data were analyzed using
Student’s two-tailed unpaired t-test when examining both sexes together (e.g., PND1),
while sex-specific effects were analyzed by two-way ANOVA followed by a Holm-Sidakcorrected multiple comparisons test. All immunoblot data were analyzed using Student’s
two-tailed unpaired t-test. Triglyceride and cholesterol measurements obtained from lipid
analyses were analyzed by two-way ANOVA, followed by Holm-Sidak-corrected multiple
comparisons test between ∆9-THC offspring and their sex-matched controls. Grubbs’ test
was utilized to detect any statistical outliers.
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